Join BOPA
Back to news articles

Registration Now OPEN – BOPA Introduction to Oncology Course 2023 Leeds Cohort

By BOPA E&T Subcommittee on 9th January 2023

Registration will initially open for delegates who wish to attend both study days.For delegates who wish to attend one of the two days only, registration will be available from Friday 13th January 2023.

The BOPA Introduction to Oncology Course 2023 Leeds Cohort
  • WHEN: Tuesday 7th March 2023 & Wednesday 8th March 2023
  • WHERE: The Bridge Conference Centre, Rider Street, Leeds LS9 7BQ (1.3 miles (10 min Taxi or 20min walk) from Leeds Train Station)
  • COST: Completely FREE for BOPA Paid Members (unfortunately travel expenses are not included)
  • CONTENT: Click here for the agenda
  • REGISTER: Via this link
  • PLACES: Only 50 places are available for each day, register early to avoid disappointment!
  • QUESTIONS – Please email:

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article